IP Library Granted Patent US 10,912,744
Granted Patent B2
US 10,912,744 · App. 16/579,054 · Granted Feb 9, 2021

Therapeutic formulation for reduced drug side effects

Inventor: Subhash Desai (Wilmette, IL)
Assignee: KemPharm, Inc.
A61K31/137A61K9/14A61K9/19A61K9/4866A61K31/135A61K31/165A61K31/4168Y10T428/2982
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,912,744
App. No.
16/579,054
Granted
Feb 9, 2021
Kind
B2
Abstract

The present invention provides drug therapy formulations for reducing the side effects associated with a therapeutic. In some embodiments, the present invention provides a reduction in sleep- and diet-related side effects associated with a therapeutic.

Claims (10)

1. A pharmaceutical composition consisting of dexamphetamine nanoparticles, wherein the dexamphetamine nanoparticles have a mean diameter of up to 50 nm, and guanfacine.

2. The pharmaceutical composition of 1 , wherein the dexamphetamine nanoparticles have a mean diameter of up to 25 nm.

3. A pharmaceutical composition consisting of:

a. a component formulated for rapid release consisting of dexamphetamine nanoparticles wherein the dexamphetamine nanoparticles have a mean diameter of up to 50 nm; and

b. component formulated for delayed release consisting of guanfacine.

4. The pharmaceutical composition of 3 , wherein the dexamphetamine nanoparticles have a mean diameter of up 25 nm.

5. A pharmaceutical composition consisting of:

a. a component formulated for rapid release consisting of amphetamine nanoparticles wherein the amphetamine nanoparticles consist of levoamphetamine and dexamphetamine, and the amphetamine nanoparticles have a mean diameter of up to 50 nm; and

b. a component formulated for delayed release consisting of guanfacine.

6. The pharmaceutical composition of claim 5 , wherein said amphetamine nanoparticles have a mean diameter of up to 25 nm.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Mar 13, 2026
From: ALTER DOMUS (US) LLC
To: ZEVRA THERAPEUTICS, INC.
Reel/Frame 075080/0907 →
SECURITY INTEREST Recorded Apr 8, 2024
From: ZEVRA THERAPEUTICS, INC.
To: ALTER DOMUS (US) LLC
Reel/Frame 067040/0637 →
CHANGE OF NAME Recorded Feb 23, 2024
From: KEMPHARM, INC.
To: ZEVRA THERAPEUTICS, INC.
Reel/Frame 066664/0108 →
CORRECTIVE ASSIGNMENT TO CORRECT THE EXECUTION DATE OF ASSIGNOR, GENCO SCIENCES LLC, INCORRECTLY RECORDED AS 09-27-2017 PREVIOUSLY RECORDED AT REEL: 053863 FRAME: 0360. ASSIGNOR(S) HEREBY CONFIRMS THE ASSOGNMENT. Recorded Oct 6, 2020
From: GENCO SCIENCES LLC
To: KEMPHARM, INC.
Reel/Frame 053985/0770 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2020
From: GENCO SCIENCES LLC,
To: KEMPHARM, INC.
Reel/Frame 053863/0360 →
Continuity (4)
Continuation 13093662 · Apr 25, 2011
Provisional Application 61369338 · Jul 30, 2010
Provisional Application 61327486 · Apr 23, 2010
Related Publication 20200054582A1 · Feb 20, 2020